Supplementary Tables 3, 5, 6 and 7 from CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients

Supplementary Tables 3, 5, 6 and 7. Supplementary Table 3: Contains the results of the differential gene expression analysis between CD44s HEK and native HEK cells (log ratios on the gene level and FDR corrected p-values) Supplementary Table 5: Contains the results of differential gene expression analysis between a subgroup of TCGA UECE patients expressing either CD44s or CD44v as major isoform (log ratio and FDR corrected p-values) Supplementary Table 6: Contains the results of differential gene expression analysis between a subgroup of TCGA BRCA patients expressing either CD44s or CD44v as major isoform (log ratio and FDR corrected p-values) Supplementary Table 7: Contains the results of differential gene expression analysis between a subgroup of TCGA LUSC patients expressing either CD44s or CD44v as major isoform (log ratio and FDR corrected p-values)